Biotech company 10x Genomics has sued competitor Curio Bioscience in Delaware federal court over allegations that Curio infringed its patents related to genetic analysis, adding to a web of patent ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.29.

10x Genomics has marked a new phase in its remarkable expansion by opening a modern office building that has just sprouted in Pleasanton.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

10x Genomics has bought a big Pleasanton site where the fast-growing biotech company intends to establish a major hub for its local operations.

10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. Learn why we recommend a Buy rating for TXG stock.

At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product ...

View 10x Genomics Inc Class A TXG stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biotech company 10x Genomics has sued competitor Curio Bioscience in Delaware federal court over allegations that Curio infringed its patents related to genetic analysis, adding to a web of patent ...

We discussed 10x Genomics, Inc. (NASDAQ:TXG) in another article and shared the list of biggest genomics companies in the world.